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The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services 
worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource 
constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus 
statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of 
three rounds with 40 international experts in head and neck cancer surgical, radiation, and medical oncology, 
representing 35 international professional societies and national clinical trial groups. Endorsed by 39 societies and 
professional bodies, these consensus practice recommendations aim to decrease inconsistency of practice, reduce 
uncertainty in care, and provide reassurance for clinicians worldwide for head and neck surgical oncology in the 
context of the COVID-19 pandemic and in the setting of acute severe resource constraint and high risk of infection to 
patients and staff.
Introduction
WHO declared the COVID-19 outbreak to be a global 
pandemic on March 11, 2020.1 The speed and scale of the 
spread of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) has resulted in unprecedented pressures 
on health services worldwide.2–4 The need for hospital-
isation and mechanical ventilation in intensive care for a 
considerable proportion of patients, in addition to staff 
shortages due to illness and concerns of viral trans-
mission to health-care workers and other patients, have 
led to a severe curtailment of health-care capacity and 
resources.5–8 System constraints preventing the delivery 
of timely and comprehensive care, the fear of viral 
transmission, and poor clinical outcomes of patients 
with head and neck cancer developing COVID-19 during 
the perioperative period have greatly impacted surgical 
practice and decision making in this cancer setting.9–14 
Many clinical services have had to substantially reduce, 
or even cease, their routine clinical activity.15–17 Further-
more, services have had to adapt by adopting new 
strategies for care delivery, with the aim of releasing 
capacity and reducing the risk of nosocomial infection to 
patients and staff due to travel and face-to-face contact in 
hospital.18,19
In the setting of the COVID-19 pandemic, adherence to 
previously established standards of care have proven 
difficult.20 Patient evaluation (including use of flexible 
nasendoscopy and diagnostic imaging), achieving target 
wait times for surgery, and oncological surveillance 
have all been affected.21 In this climate of constrained 
resources, consideration should be given to prioritisation 
of surgical cases and innovative methods of patient 
evaluation and surveillance.14 Individual institutions and 
national professional organisations have produced 
guidelines and clinical protocols during the pandemic.22–27 
By necessity, such guidelines have been developed 
hastily, usually by individuals or small groups of 
clinicians, and have often not been subjected to the usual 
processes of peer review that were implemented before 
the COVID-19 pandemic. As a result, there has been 
some confusion among head and neck cancer surgeons 
as to which advice should be followed.
The Head and Neck Cancer International Group 
(HNCIG), a collaboration of 20 national clinical trial 
groups for head and neck cancer across three continents, 
identified an urgent need for consensus practice 
recommendations for head and neck surgical oncology 
that could be applied globally in the setting of severely 
constrained resources. To address this need, we rapidly 
developed expert consensus recommendations for the 
management of surgical patients with head and neck 
cancer during the COVID-19 pandemic using a modified 
online Delphi process with representation from the 
relevant multi disciplinary bodies worldwide.
Data collection
Participant selection
In total, 35 international and national head and neck 
oncology organisations were invited to participate by 
the steering committee, which was composed of the 
members of the HNCIG Surgical Committee. The 
invited organisations included all 20 clinical trial groups 
of the HNCIG, who were invited to nominate a surgical 
representative to be part of the consensus panel. 
Member groups were the Canadian Cancer Trials 
Group, Cancer Trials Ireland, the Danish Head and 
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Neck Cancer Group, the Dutch Head and Neck Society, 
the Eastern Cooperative Oncology Group and the 
American College of Radiology Imaging Network, the 
European Organ isation for Research and Treatment of 
Cancer, the French Head and Neck Cancer Group, 
Fudan University Shanghai Cancer Center, the German 
Interdisciplinary Working Group for Head and Neck 
Tumors, the Hellenic Cooperative Oncology Group, 
Hong Kong Naso pharyngeal Carcinoma Study Group, 
the Japanese Clinical Oncology Group and The Head 
and Neck Cancer Study Group, the National Cancer 
Centre Singapore, the National Cancer Research 
Institute UK, the North West Italian Oncology Group, 
NRG Oncology-Head and Neck Cancer Committee, the 
Spanish Head and Neck Cancer Cooperative Group, 
Taiwan Cooper ative Oncology Group, Tata Memorial 
Centre, and Trans-Tasman Radiation Oncology Group.
To ensure adequate representation from all continents 
and geographical regions, the following international 
and national head and neck surgical societies were 
also invited to nominate surgical representatives: the 
European Head and Neck Society, the African Head and 
Neck Society, the Latin American Cooperative Oncology 
Group, the International Committee of the American 
Head and Neck Society, the International Federation of 
Head and Neck Oncological Societies, the International 
Association of Oral Oncology, the Korean Society of Head 
and Neck Surgery, the National Cancer Centre–Chinese 
Academy of Medical Sciences and Peking Union Medical 
College Cancer Hospital, the United Arab Emirates 
Otorhinolaryngological and Head and Neck Society 
(Middle East), the British Association of Head and Neck 
Oncologists, the Head and Neck Cancer Society of 
Turkey, and the Australian and New Zealand Head and 
Neck Cancer Society.
To ensure multidisciplinary representation, the following 
international organisations were also invited to nominate 
medical and radiation oncologists: the American Society of 
Clinical Oncology, the American Society for Radiation 
Oncology, and the European Society for Radiotherapy 
and Oncology. These leading radio therapy and medical 
oncology societies all have global membership.
All invited organisations agreed to participate and each 
organisation’s governing executive made their respective 
nomination. Nominees had to be currently practising as 
a head and neck cancer clinician, considered to be a 
national or international expert, and be willing to 
complete all three rounds of the online Delphi process 
within 14 days. All partici pants were included in the 
manuscript authorship.
Consensus formation
To achieve consensus, an online modified Delphi process 
was done over three rounds. Nominated experts were 
invited to complete an anonymous online questionnaire, 
delivered by the Qualtrics online survey platform 
(Qualtrics, Salt Lake City, UT, USA). The survey included 
three main sections: clinical protocols, treatment 
protocols, and prioritisation of treatment, all within the 
context of severe resource constraint and risk of 
transmission caused by the prevalence of SARS-CoV-2 in 
the patient population. An overview of the modified 
Delphi process is shown in the figure.
Participants were invited by email to complete each 
round of the survey, which was open for a period of 24 h. 
A reminder email was sent at 2 h and 1 h before the 
deadline to prompt participants who had not yet 
completed their responses.
When making their recommendations, participants 
were instructed to consider an extremely constrained 
setting in terms of capacity and resources (including a 
severe reduction in staffing, operating room capacity, 
inpatient and intensive care bed capacity) compared with 
baseline before the COVID-19 pandemic.
After each round, data were analysed by the multi-
disciplinary steering group and predetermined criteria for 
agreement were applied. These criteria were set a priori in 
the protocol before the start of the project and were 
extrapolated from the RAND method.28 A threshold of 80% 
and above was used to signify strong agreement for a 
statement; whereas, 20% and below indicated strong 
disagreement. For each statement, the Delphi process was 
stopped either when strong agreement was reached or 
after completion of three rounds, whichever occurred first. 
Items that reached strong agreement were dropped from 
subsequent rounds. Additionally, after the third round, 
statements that did not reach the strong agreement 
threshold but reached a threshold of 67% and over were 
considered to have reached agreement.13
Results from the first and second rounds were emailed 
to participants to allow them to be reviewed before 
the next round opened. Participants were repeatedly 
reminded that they could change their responses in 
the subsequent round for questions that had not yet 
reached strong agreement. Results from the first and 
second rounds were also presented immediately above 
the relevant question on Qualtrics. When necessary, 
questions were iteratively revised between rounds before 
being repiloted, and a few new questions were introduced 
to provide more granularity to the topic or to reduce 
ambiguity on the phrasing of a previous question. The 
resulting recom mendations were then circulated to the 
partici pating bodies and societies for endorsement. 
Further more, we received requests from other profes-
sional bodies of head and neck surgical oncology to 
endorse the recommendations.
The project was given a waiver by the Research Ethics 
Department at the University of Birmingham 
(Birmingham, UK) and by the Institutional Review Board 
at Stanford University (Paolo Alto, CA, USA).
Findings
Invitations were sent to 40 nominees representing 
35 societies and groups. These nominees included 
Germany (Prof A Dietz PhD); 
Division of Otolaryngology, 
University of Cape Town, 
Cape Town, South Africa 
(Prof J J Fagan MBChB); 
Department of 
Otorhinolaryngology–Head 
and Neck Surgery, Odense 
University Hospital and 
University of Southern 
Denmark, Odense, Denmark 
(Prof C Godballe PhD); 
Department of Head and Neck 
Surgery, Poznan University of 
Medical Sciences, Greater 
Poland Cancer Centre, Poznan, 
Poland (Prof W Golusiński PhD); 
Department of 
Otolaryngology–Head and 
Neck Surgery, Faculty of 
Medicine and Graduate School 
of Medicine, Hokkaido 
University, Sapporo, Japan 
(Prof A Homma PhD); 
Department of 
Otolaryngology–Head and 
Neck Surgery, Atilim University 
Faculty of Medicine, Ankara, 
Turkey (Prof S Hosal MD); 
Department of Head and Neck 
Surgery, National Cancer 
Centre and Singapore General 
Hospital, Singapore 
(Prof N G Iyer MD); Department 
of Otorhinolaryngology, Yonsei 
University, Seoul, South Korea 
(Prof Y W Koh PhD); Department 
of Otolaryngology, Komfo 
Anokye Teaching Hospital, 
Kwame Nkrumah University of 
Science and Technology, School 
of Medical Science, Kumasi, 
Ghana (A Konney MD); 
Department of Head and Neck 
Surgery, University of 
Sao Paulo Medical School, 
Sao Paulo, Brazil 
(Prof L P Kowalski MD); 
Department of Head and Neck 
Surgery and 
Otorhinolaryngology, 
A C Camargo Cancer Center, 
Sao Paulo, Brazil 
(Prof L P Kowalski); Department 
of Otolaryngology–Head and 
Neck Surgery, Zucker School of 
Medicine, Northwell Health 
Cancer Institute, New York, NY, 
USA (D Kraus MD); Department 
of Otolaryngology–Head and 
Neck Surgery, Cochin Cancer 
Research Centre, Cochin, India 
(Prod M A Kuriakose MD); First 
Department of 
Otolaryngology–Head and 
Neck Surgery, Faculty of 
Medicine, National and 
Kapodistrian University of 
Athens, Athens, Greece 
(E Kyrodimos PhD); Department 
of Head and Neck Surgery,
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33 surgeons, three radiation oncologists, two medical 
oncologists, and two maxillofacial surgeons. The full list 
is provided in the appendix (p 1). All 40 experts 
participated in each of the three rounds of the survey, 
with no dropouts or substitutions between rounds. The 
recom mendations were endorsed by 39 societies and 
pro fessional bodies (panel 1).
In total, 78 questions were asked in the first round 
with an average completion time of 80·0 min, 
81 questions in the second round with an average 
completion time of 33·2 min, and 41 questions in the 
third round with an average completion time of 
19·3 min.
The rates of agreement reported reflect when the item 
first reached one of the agreement thresholds that were 
outlined in the data collection section. These rates 
might have been after one, two, or three rounds of 
questioning. Full results of each round are provided in 
the appendix (pp 2–5).
Clinical protocols and procedures
A summary of the consensus findings for clinical 
management is available in table 1. Experts reached a 
strong agreement that flexible nasendoscopy is appro-
priate only if adequate personal protection equipment 
(PPE) is available for clinicians in patients with either 
symptoms or examination findings suggestive of a new 
primary head and neck cancer or recurrence (92·5%), 
and in patients with concern for critical airway 
obstruction (97·5%).
Experts also reached strong agreement (80·0%) that 
flexible nasendoscopy is not appropriate in patients with 
no history of head and neck cancer who present with low-
risk symptoms (eg, globus pharyngeus). In asymptomatic 
University of Texas MD 
Anderson Cancer Center, 
Houston, TX, USA 
(Prof S Y Lai PhD); Department 
of Otolaryngology and Head 
and Neck Surgery, Amsterdam 
University Medical Centre, 
Cancer Center Amsterdam, 
VU University, Amsterdam, 
Netherlands 
(Prof C R Leemans PhD); 
Department of Otolaryngology 
and Head and Neck Surgery, 
St James’s Hospital and The 
Royal Victoria Eye and Ear 
Hospital, Dublin, Ireland 
(P Lennon MD); Foundation 
IRCCS, Division of Medical 
Oncology (Prof L Licitra MD), 
and Department of 
Otorhinolaryngology, 
Maxillofacial and Thyroid 
Surgery (Prof C Piazza MD), 
National Institute of Cancer of 
Milan, University of Milan, 
Milan, Italy; Department of 
Otolaryngology, National 
Taiwan University Hospital and 
College of Medicine, Taipei, 
Taiwan (Prof P-J Lou MD); 
Department of Otolaryngology 
Head and Neck Surgery, 
St Vincent’s Hospital, 
Melbourne, VIC, Australia 
(B Lyons MBBS); Department of 
Otolaryngology and Head and 
Neck Surgery, Hôpital 
Européen Georges-Pompidou, 
Assistance Publique-Hôpitaux 
de Paris, Université Paris 
Descartes, Paris, France 
(Prof H Mirghani PhD); 
Department of 
Otolaryngology–Head and 
Neck Surgery and Department 
of Oncology, University of 
Western Ontario, London, ON, 
Canada (A C Nichols MD); 
Department of 
Otolaryngology–Head and 
Neck Surgery 
(Prof B J Panizza MBBS) and 
Department of Cancer Services 
(Prof S V Porceddu MD), Princess 
Alexandra Hospital and Faculty 
of Medicine, University of 
Queensland, Brisbane, QLD, 
Australia; Department of 
Otolaryngology and Head and 
Neck Surgery, Hospital 
Universitario Lucus Augusti, 
Lugo, Spain 
(P Parente Arias PhD); 
Department of Otolaryngology 
and Head and Neck Surgery, 
Winship Cancer Institute, 
Emory University, Atlanta, GA, 
USA (M R Patel MD); 
Department of Medical 
Oncology, Peter MacCallum 
Cancer Centre and Sir Peter
Delphi survey
preparation
Topics and response items prepared
Input from: literature search, head and neck cancer communications, HNCIG board members
Survey piloted by external experts and 
feedback incorporated
Round 1 Online survey data collection
78 items evaluated 
40 of 40 (100%) experts participated
Online survey data collection
81 items evaluated 
40 of 40 (100%) experts participated
Results analysed by steering committee
30 items reached
consensus
Six items
modified for
clarity
Nine items
added
Results analysed by steering committee
Round 2 First round results distributed to participants via email and 
embedded in second round online survey
Revised survey piloted by external experts
42 items reached
consensus
Two items
modified for 
clarity
No items added
Revised survey piloted by external experts
Online survey data collection
41 items evaluated 
40 of 40 (100%) experts participated
Results analysed by steering committee
Round 3 Second round results distributed to participants via email 
and embedded in third round online survey
13 items reached
consensus
18 items did not 
reach consensus
+72 items reaching
consensus in rounds 1 and 2
Delphi consensus recommendations prepared by steering 
committee and endorsed by 39 professional societies and groups
Figure: HNCIG modified Delphi process
HNCIG=Head and Neck Cancer International Group.
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patients with a previous history of head and neck cancer 
attending clinic for routine follow-up, there was strong 
agreement (97·5%) that flexible nasendoscopy is not 
appropriate without adequate PPE. However, experts 
could not agree on whether flexible nasendoscopy in these 
patients is appropriate if PPE is available. A majority of 
respondents (60·0%) believed that it was not appropriate 
to use flexible nasendoscopy at all in this cohort.
When confirming a diagnosis of head and neck cancer, 
there was strong agreement (92·5%) that a positive 
cytohistological result from fine needle aspiration or core 
biopsy of a suspicious node and suspicious imaging 
together are acceptable confirmations of a cancer dia-
gnosis, even in the absence of a biopsy of the primary 
tumour site. There was also strong agreement that 
suspicious findings on CT or MRI (80·0%), or PET-CT 
(82·5%) scans alone, are not acceptable to confirm a 
cancer diagnosis.
There was also strong agreement (85·0%) that if a 
tumour can be biopsied under local anaesthesia, then a 
full panendoscopy (laryngoscopy, hypo phar yngoscopy, 
and upper oesophagoscopy) under general anaesthesia is 
not required. However, if general anaes thesia is needed to 
biopsy the tumour, there was agreement (67·5%) that a 
full panendoscopy should be done at the same time.
In routine patients with head and neck cancer 
3 months or more after surgery, there was strong 
agreement (80·0%) on monitoring follow-up through 
video or phone consultations, with face-to-face review 
only in the case of suspicious findings. There was also 
agreement (70·0%) that it is appropriate to combine 
routine face-to-face and video or phone consultations. 
However, there was no agreement (47·5%) that video 
or phone consultations alone is an appropriate method 
of follow-up for these patients. There was strong 
agreement (100·0%) that it is not appropriate to stop 
follow-up altogether. There was also agreement (67·5%) 
that the normal frequency of follow-up should be 
maintained.
There was strong agreement (100·0%) that the 
COVID-19 status of a patient should be considered before 
surgery. To make a positive diagnosis of COVID-19, there 
was strong agreement (80·0%) that a positive laboratory 
test alone would be sufficient as the minimum criterion. 
There was also agreement (72·5%) that a positive clinical 
history and a positive laboratory test together are 
acceptable minimum criteria. Furthermore, experts 
agreed (70·0%) that it is not sufficient to use a positive 
clinical history (including symptoms) alone to make a 
COVID-19 diagnosis, and strongly agreed (100·0%) that 
positive chest imaging alone is also not sufficient for 
diagnosis. There was no agreement regarding use of 
positive clinical history and positive imaging together 
(57·5%) or use of clinical history, positive laboratory test, 
and positive imaging altogether (52·5%) as the minimum 
criteria for a diagnosis of COVID-19.
When operating on a patient with confirmed or highly 
suspected COVID-19 and who does not have indications 
for emergency intervention (eg, no impending airway 
obstruction), there was strong agreement (95·0%) that 
the operation should be postponed until both the 
patient’s symptoms resolve and a negative COVID-19 
result is obtained on repeat laboratory testing.
Treatment protocols
Early head and neck cancer
In the case of an early T1–T2 N0 oral cancer, there was 
strong consensus (95·0%) that it is not acceptable to 
delay surgery for more than 8 weeks from diagnosis. 
Among this group of respondents, 47·5% would not 
accept delaying surgery for more than 4 weeks from 
MacCallum Department of 
Oncology, University of 
Melbourne, Melbourne, VIC, 
Australia (Prof D Rischin MD); 
Department of Surgery, School 
of Medicine, Universidad de 
Antioquia–Hospital 
Universitario San Vicente 
Fundación, Medellin, Colombia 
(A Sanabria PhD); CEXCA Centro 
de Excelencia en Enfermedades 
de Cabeza y Cuello, Medellin, 
Colombia (A Sanabria); 
Department of Otolaryngology 
and Head and Neck Surgery, 
Radboud University Medical 
Center, Nijmegen, Netherlands
Panel 1: Bodies and societies endorsing the recommendations
• Head and Neck Cancer International Group
• African Head and Neck Society
• American Society for Radiation Oncology
• Associazione Italiana Oncologia Cervico-Cefalica
• Australian and New Zealand Head and Neck Cancer Society
• Australian Society of Otolaryngology
• British Association of Head and Neck Oncologists
• Canadian Cancer Trials Group
• Cancer Trials Ireland
• Danish Head and Neck Cancer Group
• Dutch Head and Neck Society
• European Head and Neck Society
• European Organization for Research and Treatment of Cancer
• European Society for Radiotherapy and Oncology
• French Head and Neck Cancer Group
• German Interdisciplinary Working Group for Head and Neck Tumors
• Head and Neck Cancer Society, Singapore
• Head and Neck Cancer Society of Turkey
• Head and Neck Cancer Study Group of the Japan Clinical Oncology Group
• Hellenic Cooperative Oncology Group
• Korean Society of Head and Neck Surgery
• Hong Kong Nasopharyngeal Carcinoma Study Group
• Hong Kong Head and Neck Society
• International Committee of the American Head and Neck Society
• International Federation of Head and Neck Oncological Societies
• Latin American Clinical Oncology Group
• National Cancer Center–Chinese Academy of Medical Sciences and Peking Union 
Medical College Cancer Hospital
• National Cancer Centre Singapore
• UK National Cancer Research Institute Head and Neck Group
• North West Italian Oncology Group
• NRG Oncology Head and Neck Cancer Committee
• Spanish Head and Neck Cancer Cooperative Group
• Spanish Otorhinolaryngology and Head and Neck Surgery Society
• Spanish Oral, Maxillofacial and Head and Neck Surgery Society
• Taiwan Cooperative Oncology Group
• Taiwan Head and Neck Society
• Tata Medical Center
• Trans-Tasman Radiation Oncology Group
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diagnosis; whereas, 55·0% would accept delaying 
surgery for up to 8 weeks. There was also strong agree-
ment (100·0%) against palliation as primary treatment 
in the setting of anticipated delay to surgery. If delay 
to surgery is anticipated to be between 4 weeks and 
8 weeks, there was strong agreement that immediate 
treat ment with alternative therapies to surgery (eg, 
radio therapy) was not acceptable (82·5%), and that 
serial monitoring is acceptable (87·5%), with consider-
ation of surgery or alternative therapies if the tumour 
progresses clinically significantly. If surgery is not anti-
cipated to occur within 8 weeks, there was pre ferential 
agreement (67·5%) to use serial moni toring, with no 
agreement (45·0%) on treating with primary radio-
therapy in such a case.
In the case of an early T1 N0 laryngeal cancer, there 
was agreement (72·5%) that surgery could be delayed 
for more than 4 weeks, but only 47·5% of respondents 
agreed that surgery could be delayed for up to 8 weeks. 
There was strong agreement (92·5%) not to delay 
surgery beyond 8 weeks. There was agreement (70·0%) 
that it is acceptable to treat immediately with radio-
therapy as an alternative to surgery. If a delay to surgery 
of 4–8 weeks is anticipated, there was agreement (67·5%) 
that radiotherapy should be recom mended immediately 
instead of surgery; whereas, if a delay of more than 
8 weeks is anticipated, there was strong agreement 
(92·5%) that radiotherapy should be recommended 
immediately over surgery. There was agreement (75·0%) 
that serial monitoring should not be used and strong 
agreement (100%) that palliative treatment as the only 
treatment was not appropriate in this setting.
Advanced head and neck cancer
In the case of an advanced head and neck cancer that 
would require extended operative time and extended 
hospital stay, intensive care, or both (eg, T4 N1 laryngeal 
cancer, N2b oral cancer, or a patient requiring bone 
resection such as maxillectomy), there was strong 
agreement (87·5%) that it is not acceptable to delay 
surgery beyond 4 weeks of diagnosis, as per previous 
standards of care. If surgery could not occur within this 
timeframe, there was strong agreement (90%) that 
alternative treatment such as radiotherapy or chemo-
radiotherapy should be given immediately. There was no 
consensus regarding the provision of induction (metro-
nomic) chemotherapy until surgery is possible, with only 
50·0% of respondents supporting this form of treatment 
if surgery is not anticipated within an acceptable time-
frame. There was strong agreement (86·2%) against use 
of serial monitoring or palliation as the only treat ment in 
these situations.
Differentiated thyroid cancer
In the case of a differentiated thyroid cancer (eg, T1–T3 
or N0–N1b) with no adverse features (no extension into 
strap muscles, trachea or oesophageal musculature, no 
Agreement level
Clinical and diagnostic procedures
Use of flexible nasendoscopy
For patients with symptoms or signs suggestive of a new primary cancer or 
recurrence: use flexible nasendoscopy only if adequate PPE is available and do 
not use flexible nasendoscopy in absence of adequate PPE
Strong agreement
For patients with concern for critical airway obstruction: use flexible 
nasendoscopy only if adequate PPE is available and no not use flexible 
nasendoscopy in absence of adequate PPE
Strong agreement
For asymptomatic patients with a previous history of head and neck cancer 
attending clinic for routine follow-up: do not use flexible nasendoscopy in 
absence of adequate PPE
Strong agreement
For patients with no history of head and neck cancer presenting with low-risk 
symptoms (eg, globus pharyngeus): do not use flexible nasendoscopy
Strong agreement
To confirm a diagnosis of head and neck cancer
Positive fine needle aspiration or core biopsy of a suspicious lymph node and 
suspicious imaging together are acceptable
Strong agreement
Suspicious findings on imaging, whether CT, MRI, or PET-CT scans alone, 
without biopsy, are not acceptable
Strong agreement
If a biopsy under local anaesthesia can be done, no panendoscopy is needed Strong agreement
If a biopsy under general anaesthesia is needed, a full panendoscopy should be 
done at the same time
Agreement
Follow-up of patients with head and neck cancer ≥3 months after surgery
Use video or phone consultations, with face-to-face reviews only in the case of 
suspicious findings
Strong agreement
Use a combination of routine scheduled face-to-face and video or phone 
consultations
Agreement
Do not stop follow-up completely Strong agreement
Maintain the normal frequency of follow-up Agreement
Minimum criteria required for diagnosing a patient with COVID-19 before head and neck cancer surgery
COVID-19 status should be considered before surgery Strong agreement
Positive laboratory test alone is sufficient Strong agreement
Positive clinical history and positive laboratory test together are sufficient Agreement
Positive clinical history (including symptoms) alone is not sufficient Agreement
Positive chest imaging alone is not sufficient Strong agreement
Delay of surgery in patients with confirmed or highly suspected COVID-19, with no indication for emergency 
intervention
Delay operation until patient symptoms resolve and negative COVID-19 repeat 
laboratory testing
Strong agreement
Treatment protocols
For T1–T2 N0 oral cancer
Operate within 8 weeks from diagnosis Strong agreement
Do not delay surgery for up to 12 weeks from diagnosis Strong agreement
If surgery delay of 4–8 weeks is anticipated, do not treat immediately with 
alternative treatments such as radiotherapy
Strong agreement
If surgery delay of 4–8 weeks is anticipated, use serial monitoring with surgery 
or alternative treatment (eg, radiotherapy) only if tumour progresses clinically 
significantly
Strong agreement
If surgery delay of >8 weeks is anticipated, use serial monitoring, with surgery or 
alternative treatment (eg, radiotherapy) only if tumour progresses clinically 
significantly
Agreement
If surgery delay of any duration is anticipated, do not treat with palliation as 
primary treatment
Strong agreement
For early T1 N0 laryngeal cancer
Can delay surgery for >4 weeks, if necessary Agreement
Do not delay surgery beyond 8 weeks Strong agreement
Treat immediately with radiotherapy as an alternative to surgery Agreement
(Table 1 continues on next page)
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critical airway compression, and no imminent risk to or 
involvement of the recurrent laryngeal nerve), there 
was strong agreement (82·5%) that it was acceptable to 
delay surgery for up to 12 weeks from diagnosis. There 
was agreement that delaying surgery for up to 18 weeks 
(70·0%) or more (77·5%) is not appropriate. There was 
also agreement (77·5%) against delaying surgery 
indefinitely, with serial monitoring until pro gression. 
However, if surgery was not anticipated to occur within 
the acceptable timeframe, then there was strong 
consensus (96·8%) to use serial monitoring and only 
consider surgery if the tumour progresses. There 
was also strong consensus against treating with radio-
active iodine or radiotherapy (96·8%), or considering 
palliative treatment (100·0%) as the primary treatment 
option.
In the case of a T1–T2 differentiated thyroid cancer of 
less than 4 cm, there was strong agreement (82·5%) that 
nodules directly abutting the airway but not invading it 
should be considered as an indication to operate within 
4 weeks. There was strong agreement that gross extra-
thyroidal extension invading strap muscles only (85·0%), 
or regional lymph node metastasis (92·5%) were not 
indications for expediting surgery within 4 weeks. There 
was no agreement (60·0% in support) on a posterior 
nodule in the tracheoeso phageal groove.
Monitoring during delay to surgery
When surgery is delayed because of system constraints, 
there was strong agreement (92·5%) to use serial 
monitoring to assess tumour progression while waiting 
for definitive treatment, and any evidence of tumour 
progression should prompt re-evaluation of treatment 
options or reprioritisation (100·0%).
Actions to optimise resources and reduce risk to patients and 
staff
Experts were asked about the acceptability of avoiding 
particular surgical procedures during a time of system 
constraints to optimise available resources (eg, to release 
bed resources, to decrease PPE use, to decrease operative 
time use) and to reduce the risk to patients and staff of 
nosocomial transmission of SARS-CoV-2.
There was strong agreement that only experienced 
senior surgeons should operate on patients (80·0%) 
and that a tracheostomy should be avoided in a patient 
with oro pharyngeal cancer undergoing transoral 
surgery (87·5%). There was agreement to accept less 
monitoring after surgery (eg, no intensive care bed 
or step-down unit) than would usually be used for such 
a case (65·0%), and to avoid primary free flap recon-
struction and instead use local or pedicled flap recon-
struction (72·5%).
There was strong agreement that the following would 
not be appropriate: avoiding primary free flap recon-
struction and instead operating delayed reconstruction at 
a later date (80·0%); avoiding salvage surgery (87·5%); 
and avoiding neck dissection or sentinel node biopsy in a 
radiologically N0 neck at risk of occult metastasis in a 
T1–T2 (85·0%) and T3–T4 (92·5%) oral or oropharyngeal 
cancer. There was agreement to not avoid a tracheostomy 
in an advanced T2–T3 oral cancer requiring free flap 
(67·5%).
There was no agreement on doing a sentinel node 
biopsy instead of elective neck dissection for T1–T2 oral 
cancer or melanoma (45·0%) or avoiding a neck dis-
section or sentinel node biopsy in a radiologically N0 neck 
in a case of cutaneous melanoma (35·0%).
Agreement level
(Continued from previous page)
If surgery delay of 4–8 weeks is anticipated, recommend radiotherapy 
immediately instead of surgery
Agreement
If surgery delay of >8 weeks is anticipated, recommend radiotherapy 
immediately instead of surgery
Strong agreement
Do not use serial monitoring with treatment only if tumour progresses Agreement
Do not treat with palliation as primary treatment Strong agreement
For advanced head and neck cancer
Do not delay surgery; operate within 4 weeks of diagnosis Strong agreement
Do not use serial monitoring or give palliation as only treatment Strong agreement
Give alternative treatment (eg, radiotherapy or chemoradiation) immediately if 
surgery cannot occur within 4 weeks
Strong agreement
For differentiated thyroid cancer (T1–T3 or N0–N1b) with no adverse features
Can delay surgery for up to 12 weeks from diagnosis, if necessary Strong agreement
Do not delay surgery for up to 18 weeks from diagnosis Agreement
If surgery is not possible within 12 weeks, use serial monitoring and only 
consider surgery if the tumour progresses clinically significantly
Strong agreement
If surgery is not possible within 12 weeks, do not treat with radioactive iodine or 
radiotherapy or palliative treatment as the primary treatment option
Strong agreement
Surgery delay
Use serial monitoring to assess tumour progression while waiting Strong agreement
Promptly re-evaluate treatment options if any evidence of tumour progression Strong agreement
Actions to optimise resources and reduce risk to patients and staff
Only experienced surgeons should operate on patients Strong agreement
Avoid a tracheostomy in an oropharyngeal cancer undergoing transoral surgery Strong agreement
Do not avoid primary free flap reconstruction in favour of delayed 
reconstruction at a later date
 Strong agreement
Avoid primary free flap reconstruction and instead do local or pedicled flap, if 
appropriate
Agreement
Do not avoid neck dissection or sentinel node biopsy in a radiologically N0 neck 
cancer at risk of occult metastasis in a T1–T2 or T3–T4 oral or oropharyngeal 
cancer
 Strong agreement
Do not avoid salvage surgery  Strong agreement
Do not avoid a tracheostomy in an advanced T2–T3 oral cancer requiring free 
flap
 Agreement
Palliative care as primary treatment in severly constrained settings
Offer primary palliation to patients with poor functional status (eg, spends 
>50% of the day in bed or Eastern Cooperative Oncology Group performance 
status 3) who have advanced disease
Strong agreement
Offer primary palliation to patients with advanced biological age (eg, >85 years) 
who have advanced stage disease
Strong agreement
PPE=personal protective equipment. Strong agreement indicates a threshold of 80% and above. Agreement indicates 
a threshold of 67% and above after the third round for statements not considered to have reached a strong agreement.
Table 1: Consensus recommendations for clinical procedures and treatment protocols in a setting of 
acute severe resource constraint resulting from the COVID-19 pandemic
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Palliative care as primary treatment
There was no consensus on whether indications for 
palliative care as the primary treatment should be 
changed in severely constrained settings (47·5%). There 
was strong consensus that patients with poor functional 
status (eg, patients who spend >50% of the day in bed or 
have a Eastern Cooperative Oncology Group performance 
status of 3 [82·5%]) and individuals with advanced 
biological age (>85 years) who have advanced-stage 
disease (92·5%) should also be offered palliative care. 
There was no consensus (60·0%) with respect to offering 
palliative care for patients who have a low cure rate 
(<20% 5-year survival).
Prioritisation in the context of severely constrained 
resources
Experts were asked to rank a group of representative 
surgical cases in order of priority for time to surgery. 
Ranking of the cases was the same in the first and second 
rounds, with the top five choices receiving higher mean 
priority ranking in the second round than in the first 
round (table 2).
Factors that participants considered to be the most 
important when prioritising patients in the setting of 
constrained resources can be found in panel 2. The order 
of selections did not change in the second round.
Discussion
These recommendations, the result of a global consensus 
process, aim to provide urgent guidance to frontline head 
and neck cancer surgeons who are overworked and 
stressed by the COVID-19 pandemic. Endorsed by 
39 national and international organisations spanning the 
globe, these recommendations should be interpreted and 
implemented in the context of national frameworks and 
local circumstances, which vary from region to region 
and from hospital to hospital, and can change rapidly. 
Additionally, these guidelines should be implemented 
with multidisciplinary discussion and consider individual 
patients’ informed wishes. We have purposefully incor-
porated flexibility in the recommendations to enable its 
adaptation to the different stages of the pandemic, 
including the recovery phase, during which capacity 
might be constrained to varying degrees for many 
months to come. Importantly, these are recom men-
dations for times of acute and severe resource limitation, 
such as the COVID-19 pandemic and natural disasters, 
and should not be continued when circum stances return 
to a typical state.
In settings with severe resource limitations, reduced 
surgical and perioperative care capacities often lead to a 
delay in the time to surgery. Therefore, new methods of 
service delivery are needed to address these challenges, 
which has been acknowledged by the experts in their 
recommendations for acceptable delay to surgery. For 
early head and neck cancer and low-risk thyroid cancer, 
when surgery is likely to be considerably delayed, serial 
monitoring might be a viable alternative with intervention 
only on progression. Consideration of non-surgical 
treatments is another alternative, but this option depends 
on the type of cancer and is much more acceptable for 
early cancer of the larynx than for other head and neck 
subsites. With serial monitoring, it is important to ensure 
that it is sufficiently frequent and in a format that allows 
early identification of progression. If these conditions are 
not possible because of resource limitation, then 
alternative treatment options should be explored instead.
The situation is different when considering advanced 
head and neck cancer. Delay or serial monitoring was 
considered far less acceptable than in the case of early 
head and neck cancer. In this setting, early consideration 
of alternative treatments, such as radiotherapy or 
chemoradiotherapy, should be considered when optimal 
primary surgery cannot be delivered in acceptable 
timeframes.
Average 
aggregated scores 
(Round 1)
Average 
aggregated scores 
(Round 2)
Head and neck surgical scenarios
1 10·5 11·7 T3 N2 oral cancer
2 10·0 10·9 T4 N1 laryngeal cancer
3 8·8 9·8 T4 N0 maxillary cancer
4 8·0 8·7 T4a N1 papillary thyroid cancer with tracheal 
invasion
5 7·9 8·0 T3 N1 carcinoma ex-pleomorphic parotid cancer
6 6·9 6·9 T1 or T2 N0 oral cancer
7 6·7 6·1 T2 N1 oropharyngeal cancer p16-negative
8 4·6 4·8 T2 N1 oropharyngeal cancer p16-positive
9 4·2 3·8 T0 N1 unknown primary
10 4·1 3·5 T2 N0 adenoid cystic oral cavity
11 3·4 2·4 T1 N0 laryngeal cancer
12 3·1 1·4 T2 N0 papillary thyroid cancer with a posterior nodule
Head and neck surgical scenarios are ranked in order of priority, from highest to lowest. Rankings did not change 
between the first round and second round, so the question was not asked again in the third round.
Table 2: Prioritisation of surgery by ranking for patients with head and neck cancer in a setting of acute 
severe resource constraint
Panel 2: Top five factors for the prioritisation of surgery in 
patients with head and neck cancer in a setting of acute 
severe resource constraint
• Chance of tumour progression with delay (risk to patient)
• COVID-19 status of patient (risk to patient, other patients, 
and staff)
• Prognosis (risk to patient)
• Availability of infrastructure to operate on patients with 
COVID-19, including personal protective equipment and 
trained staff (risk to patients and staff)
• Effectiveness and availability of alternative treatments 
(risk to patient)
Factors are listed in order of considered importance, from 
most commonly selected to least commonly selected.
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For more on the HNCIG see 
www.hncig.org
See Online for appendix
Experts strongly agreed on the need to protect staff 
and patients from SARS-CoV-2 exposure. The state-
ments reflect this agreement in their recommen dations 
to use flexible nasendoscopy only in patients who are 
deemed to be at high risk and, even then, only when 
adequate PPE is available. Experts also supported new 
modalities of follow-up, favouring remote (eg, tele-
health) consultations where possible, with face-to-face 
follow-up reserved for patients with concerning symp-
toms. Cessation of consultations altogether was not 
considered acceptable.
The COVID-19 pandemic has severely strained typical 
doctor–patient relationships.29 Clinicians are used to 
the act of prioritisation as resources are not infinite. 
However, the extent and scale to which this prioriti-
sation has been necessary during the pandemic is 
unprecedented for most practitioners. The resultant 
considerable uncertainty and ethical concerns about 
the implications for patients in terms of stage migration, 
or worse, pose the risk of so-called moral injury to 
clinicians.30 These recommendations might help to 
reduce uncertainty in care, decrease inconsistencies, 
and provide reassurance as to what is acceptable to most 
experts in the field, thus reducing the risks of stress and 
moral injury.
These recommendations have limitations. They address 
what we believe are the most important issues for head 
and neck surgeons in a setting of severely constrained 
resources, but they cannot cover every eventuality, 
especially as the nature of the pandemic changes from 
acute to endemic. Therefore, clinical networks are needed 
(locally, nationally, and internationally) to help to provide 
ongoing support to frontline clinicians and to address 
difficult issues as they arise. The HNCIG, with its global 
reach and network of partners established during this 
consensus process, is considering ways of addressing this 
need moving forward.
The original Delphi process allowed participants to 
change their past responses after being presented with 
the results of the previous round.28 In view of the 
urgency and to simplify and speed up the process, we 
presented participants with the results of the previous 
round, then invited them to change their responses in 
the next round, because there were only 2 days between 
each round. The proportions of agreement that are 
reported within the body of the recommendations are 
those that were reached at the point of first consensus. 
An agreement of 85% at the first round might have 
improved to 95% in the second or third round, but 
reaching the highest degree of consensus is not the 
purpose of this process. Therefore, the rates of strong 
agreement that are reported should not be directly 
compared with each other, as they might have been 
reached at different rounds.
Agreement is always a reflection of the participants 
and their backgrounds. In this process, most of the 
partici pants were surgeons as these were recom-
mendations for surgical practice and this should be 
taken into account when considering this statement. 
Recommen dations for head and neck cancer radio-
therapy during the COVID-19 pandemic have recently 
been published by the American Society for Therapeutic 
Radiology and Oncology and the European Society for 
Radiotherapy and Oncology.13 These recommendations 
also used an online modified Delphi process, which we 
used when designing our method. Taken together, 
these two statements will hopefully provide multi-
disciplinary services for head and neck oncology with 
comprehensive recommendations for practice during 
the COVID-19 pandemic.
Conclusion
Sadly, this pandemic is not likely to be the last disaster 
faced by our global community. Although these recom-
mendations for head and neck surgical practice have 
been developed during the COVID-19 pandemic, we 
believe that the methods used and the context of the 
questions posed means that they could be used in other 
settings of acute and severely constrained resources, as 
well as in settings with a high risk of injury to patients 
and staff. These environments could include epidemics 
and other natural disasters, such as large-scale flooding 
or earthquakes. Furthermore, we believe that the 
methods used to develop these recom mendations, the 
speed with which they were developed, and the scale of 
cooperation and collaboration between the international 
and national bodies involved is a strong example of how 
global collaboration can help to address urgent challenges 
facing clinicians in times of acute stress and disaster. We 
plan to publish the detailed methods and provide 
Search strategy and selection criteria
To identify areas of uncertainty in clinical practice caused by 
acute resource constraint and the COVID-19 pandemic, we 
did a literature search of PubMED, Embase, Medline, and 
Google that included grey literature, individual association 
correspondence, and guidelines on COVID-19 and head and 
neck cancer. We used the main search terms ‘head neck 
cancer’ and ‘COVID-19’ and searched for articles published 
between Nov 1, 2019, to April 1, 2020. We limited our 
search to papers published in English and prioritised peer-
reviewed papers, large series papers, and guidelines 
published by national or international bodies. Discussions 
with HNCIG board members highlighted areas of 
uncertainty identified in the literature, along with 
challenges to clinical practice. All issues were then collated 
into initial domains and questions formulated by the 
multidisciplinary steering group. All questions were piloted 
by three independent experts (SVP, VP, CS) for readability, 
as well as face and content validity,. Survey questions and 
the results of all three rounds are provided in the 
appendix (pp 2–5).
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open-access templates on the HNCIG website, so that 
they can be easily applied should the need arise again in 
the future.
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